Inicio
Resultado de la búsqueda
23 búsqueda de la palabra clave 'pituitary adenoma'
Clasificado(s) por (Año de edición descendente) Refinar búsqueda Genera el flujo rss de la búsqueda
Enlace permanente de la investigación
Título : Clinical biology of the pituitary adenoma Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2022 Títulos uniformes : Endocrine Reviews Idioma : Inglés (eng) Palabras clave : pituitary adenoma acromegaly prolactinoma Cushing’s disease aggressive pituitary tumor hypothalamus Resumen : All endocrine glands are susceptible to neoplastic growth, yet the health consequences of these neoplasms differ between endocrine tissues. Pituitary neoplasms are highly prevalent and overwhelmingly benign, exhibiting a spectrum of diverse behaviors and impact on health. To understand the clinical biology of these common yet often innocuous neoplasms, we review pituitary physiology, and adenoma epidemiology, pathophysiology, behavior, and clinical consequences. The anterior pituitary develops in response to a range of complex brain signals integrating with intrinsic ectodermal cell transcriptional events that together determine gland growth, cell type differentiation, and hormonal production, in turn maintaining optimal endocrine health. Pituitary adenomas occur in ten percent of the population; however, the overwhelming majority remain harmless during life. Triggered by somatic or germline mutations, disease-causing adenomas manifest pathogenic mechanisms that disrupt intra-pituitary signaling to promote benign cell proliferation associated with chromosomal instability. Cellular senescence acts as a mechanistic buffer protecting against malignant transformation, an extremely rare event. It is estimated that fewer than one thousandth of all pituitary adenomas cause clinically significant disease. Adenomas variably and adversely affect morbidity and mortality depending on cell type, hormone secretory activity, and growth behavior. For most clinically apparent adenomas, multimodal therapy controlling hormone secretion and adenoma growth lead to improved quality of life and normalized mortality. The clinical biology of pituitary adenomas and particularly their benign nature stands in marked contrast to other tumors of the endocrine system such as thyroid and neuroendocrine tumors. Mención de responsabilidad : Shlomo Melmed, Ursula B Kaiser, M Beatriz Lopes, Jerome Bertherat, Luis V Syro, Gerald Raverot, Martin Reincke, Gudmundur Johannsson, Albert Beckers, Maria Fleseriu, Andrea Giustina, John A H Wass, Ken K Y Ho Referencia : Endocr Rev. 2022 Apr 8;bnac010. DOI (Digital Object Identifier) : 10.1210/endrev/bnac010 PMID : 35395078 Derechos de uso : CC BY-NC-ND En línea : https://academic.oup.com/edrv/advance-article/doi/10.1210/endrev/bnac010/6565598 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6028 Clinical biology of the pituitary adenoma [documento electrónico] / Luis Vicente Syro Moreno, . - 2022.
Obra : Endocrine Reviews
Idioma : Inglés (eng)
Palabras clave : pituitary adenoma acromegaly prolactinoma Cushing’s disease aggressive pituitary tumor hypothalamus Resumen : All endocrine glands are susceptible to neoplastic growth, yet the health consequences of these neoplasms differ between endocrine tissues. Pituitary neoplasms are highly prevalent and overwhelmingly benign, exhibiting a spectrum of diverse behaviors and impact on health. To understand the clinical biology of these common yet often innocuous neoplasms, we review pituitary physiology, and adenoma epidemiology, pathophysiology, behavior, and clinical consequences. The anterior pituitary develops in response to a range of complex brain signals integrating with intrinsic ectodermal cell transcriptional events that together determine gland growth, cell type differentiation, and hormonal production, in turn maintaining optimal endocrine health. Pituitary adenomas occur in ten percent of the population; however, the overwhelming majority remain harmless during life. Triggered by somatic or germline mutations, disease-causing adenomas manifest pathogenic mechanisms that disrupt intra-pituitary signaling to promote benign cell proliferation associated with chromosomal instability. Cellular senescence acts as a mechanistic buffer protecting against malignant transformation, an extremely rare event. It is estimated that fewer than one thousandth of all pituitary adenomas cause clinically significant disease. Adenomas variably and adversely affect morbidity and mortality depending on cell type, hormone secretory activity, and growth behavior. For most clinically apparent adenomas, multimodal therapy controlling hormone secretion and adenoma growth lead to improved quality of life and normalized mortality. The clinical biology of pituitary adenomas and particularly their benign nature stands in marked contrast to other tumors of the endocrine system such as thyroid and neuroendocrine tumors. Mención de responsabilidad : Shlomo Melmed, Ursula B Kaiser, M Beatriz Lopes, Jerome Bertherat, Luis V Syro, Gerald Raverot, Martin Reincke, Gudmundur Johannsson, Albert Beckers, Maria Fleseriu, Andrea Giustina, John A H Wass, Ken K Y Ho Referencia : Endocr Rev. 2022 Apr 8;bnac010. DOI (Digital Object Identifier) : 10.1210/endrev/bnac010 PMID : 35395078 Derechos de uso : CC BY-NC-ND En línea : https://academic.oup.com/edrv/advance-article/doi/10.1210/endrev/bnac010/6565598 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6028 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001869 AC-2022-034 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
AC-2022-034Adobe Acrobat PDFPituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time? / Luis Vicente Syro Moreno
Título : Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time? Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2021 Títulos uniformes : Journal of the Endocrine Society Idioma : Inglés (eng) Palabras clave : Pituitary neoplasm neuroendocrine pituitary adenoma tumor Resumen : The WHO Classification of Endocrine Tumours designates pituitary neoplasms as adenomas. A proposed nomenclature change to pituitary neuroendocrine tumors (PitNETs) has been met with concern by some stakeholder groups. The Pituitary Society coordinated the Pituitary Neoplasm Nomenclature (PANOMEN) workshop to address the topic. Experts in pituitary developmental biology, pathology, neurosurgery, endocrinology, and oncology, including representatives nominated by the Endocrine Society, European Society of Endocrinology, European Neuroendocrine Association, Growth Hormone Research Society, and International Society of Pituitary Surgeons. Clinical epidemiology, disease phenotype, management, and prognosis of pituitary adenomas differ from that of most NETs. The vast majority of pituitary adenomas are benign and do not adversely impact life expectancy. A nomenclature change to PitNET does not address the main challenge of prognostic prediction, assigns an uncertain malignancy designation to benign pituitary adenomas, and may adversely affect patients. Due to pandemic restrictions, the workshop was conducted virtually, with audiovisual lectures and written précis on each topic provided to all participants. Feedback was collated and summarized by Content Chairs and discussed during a virtual writing meeting moderated by Session Chairs, which yielded an evidence-based draft document sent to all participants for review and approval. There is not yet a case for adopting the PitNET nomenclature. The PANOMEN Workshop recommends that the term adenoma be retained and that the topic be revisited as new evidence on pituitary neoplasm biology emerges. Mención de responsabilidad : Ken Ho, Maria Fleseriu, Ursula Kaiser, Roberto Salvatori, Thierry Brue, M Beatriz Lopes, Pamela Kunz, Mark Molitch, Sally A Camper, Mônica Gadelha, Luis V Syro, Edward Laws, Martin Reincke, Hiroshi Nishioka, Ashley Grossman, Ariel Barkan, Felipe Casanueva, John Wass, Adam Mamelak, Laurence Katznelson, Aart J van der Lely, Sally Radovick, Martin Bidlingmaier, Margaret Boguszewski, Jens Bollerslev, Andrew R Hoffman, Nelson Oyesiku, Gerald Raverot, Anat Ben-Shlomo, Rob Fowkes, Ilan Shimon, Hidenori Fukuoka, Alberto M Pereira, Yona Greenman, Anthony P Heaney, Mark Gurnell, Gudmundur Johannsson, Robert Y Osamura, Michael Buchfelder, Maria Chiara Zatelli, Marta Korbonits, Philippe Chanson, Nienke Biermasz, David R Clemmons, Niki Karavitaki, Marcello D Bronstein, Peter Trainer, Shlomo Melmed Referencia : J Endocr Soc. 2021 Feb 9;5(3):bvaa205. DOI (Digital Object Identifier) : 10.1210/jendso/bvaa205 PMID : 33604494 Derechos de uso : CC BY-NC-ND En línea : https://academic.oup.com/jes/article/5/3/bvaa205/6131724 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5765 Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time? [documento electrónico] / Luis Vicente Syro Moreno, . - 2021.
Obra : Journal of the Endocrine Society
Idioma : Inglés (eng)
Palabras clave : Pituitary neoplasm neuroendocrine pituitary adenoma tumor Resumen : The WHO Classification of Endocrine Tumours designates pituitary neoplasms as adenomas. A proposed nomenclature change to pituitary neuroendocrine tumors (PitNETs) has been met with concern by some stakeholder groups. The Pituitary Society coordinated the Pituitary Neoplasm Nomenclature (PANOMEN) workshop to address the topic. Experts in pituitary developmental biology, pathology, neurosurgery, endocrinology, and oncology, including representatives nominated by the Endocrine Society, European Society of Endocrinology, European Neuroendocrine Association, Growth Hormone Research Society, and International Society of Pituitary Surgeons. Clinical epidemiology, disease phenotype, management, and prognosis of pituitary adenomas differ from that of most NETs. The vast majority of pituitary adenomas are benign and do not adversely impact life expectancy. A nomenclature change to PitNET does not address the main challenge of prognostic prediction, assigns an uncertain malignancy designation to benign pituitary adenomas, and may adversely affect patients. Due to pandemic restrictions, the workshop was conducted virtually, with audiovisual lectures and written précis on each topic provided to all participants. Feedback was collated and summarized by Content Chairs and discussed during a virtual writing meeting moderated by Session Chairs, which yielded an evidence-based draft document sent to all participants for review and approval. There is not yet a case for adopting the PitNET nomenclature. The PANOMEN Workshop recommends that the term adenoma be retained and that the topic be revisited as new evidence on pituitary neoplasm biology emerges. Mención de responsabilidad : Ken Ho, Maria Fleseriu, Ursula Kaiser, Roberto Salvatori, Thierry Brue, M Beatriz Lopes, Pamela Kunz, Mark Molitch, Sally A Camper, Mônica Gadelha, Luis V Syro, Edward Laws, Martin Reincke, Hiroshi Nishioka, Ashley Grossman, Ariel Barkan, Felipe Casanueva, John Wass, Adam Mamelak, Laurence Katznelson, Aart J van der Lely, Sally Radovick, Martin Bidlingmaier, Margaret Boguszewski, Jens Bollerslev, Andrew R Hoffman, Nelson Oyesiku, Gerald Raverot, Anat Ben-Shlomo, Rob Fowkes, Ilan Shimon, Hidenori Fukuoka, Alberto M Pereira, Yona Greenman, Anthony P Heaney, Mark Gurnell, Gudmundur Johannsson, Robert Y Osamura, Michael Buchfelder, Maria Chiara Zatelli, Marta Korbonits, Philippe Chanson, Nienke Biermasz, David R Clemmons, Niki Karavitaki, Marcello D Bronstein, Peter Trainer, Shlomo Melmed Referencia : J Endocr Soc. 2021 Feb 9;5(3):bvaa205. DOI (Digital Object Identifier) : 10.1210/jendso/bvaa205 PMID : 33604494 Derechos de uso : CC BY-NC-ND En línea : https://academic.oup.com/jes/article/5/3/bvaa205/6131724 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5765 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001690 AC-2021-016 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
2021-016Adobe Acrobat PDF
Título : Pituitary society expert Delphi consensus: operative workflow in endoscopic transsphenoidal pituitary adenoma resection Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2021 Títulos uniformes : Pituitary Idioma : Inglés (eng) Palabras clave : Consensus Delphi Endoscopic endonasal Endoscopic transsphenoidal surgery Pituitary Pituitary adenoma Skull base surgery Resumen : Purpose: Surgical workflow analysis seeks to systematically break down operations into hierarchal components. It facilitates education, training, and understanding of surgical variations. There are known educational demands and variations in surgical practice in endoscopic transsphenoidal approaches to pituitary adenomas. Through an iterative consensus process, we generated a surgical workflow reflective of contemporary surgical practice. Methods: A mixed-methods consensus process composed of a literature review and iterative Delphi surveys was carried out within the Pituitary Society. Each round of the survey was repeated until data saturation and > 90% consensus was reached. Results: There was a 100% response rate and no attrition across both Delphi rounds. Eighteen international expert panel members participated. An extensive workflow of 4 phases (nasal, sphenoid, sellar and closure) and 40 steps, with associated technical errors and adverse events, were agreed upon by 100% of panel members across rounds. Both core and case-specific or surgeon-specific variations in operative steps were captured. Conclusions: Through an international expert panel consensus, a workflow for the performance of endoscopic transsphenoidal pituitary adenoma resection has been generated. This workflow captures a wide range of contemporary operative practice. The agreed "core" steps will serve as a foundation for education, training, assessment and technological development (e.g. models and simulators). The "optional" steps highlight areas of heterogeneity of practice that will benefit from further research (e.g. methods of skull base repair). Further adjustments could be made to increase applicability around the world. Mención de responsabilidad : Hani J. Marcus, Danyal Z. Khan, Anouk Borg, Michael Buchfelder, Justin S. Cetas, Justin W. Collins, Neil L. Dorward, Maria Fleseriu, Mark Gurnell, Mohsen Javadpour, Pamela S. Jones, Chan Hee Koh, Hugo Layard Horsfall, Adam N. Mamelak, Pietro Mortini, William Muirhead, Nelson M. Oyesiku, Theodore H. Schwartz, Saurabh Sinha, Danail Stoyanov, Luis V. Syro, Georgios Tsermoulas, Adam Williams, Mark J. Winder, Gabriel Zada & Edward R. Laws Referencia : Pituitary. 2021 Dec;24(6):839-853. DOI (Digital Object Identifier) : 10.1007/s11102-021-01162-3 PMID : 34231079 Derechos de uso : CC BY En línea : https://link.springer.com/article/10.1007%2Fs11102-021-01162-3 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5816 Pituitary society expert Delphi consensus: operative workflow in endoscopic transsphenoidal pituitary adenoma resection [documento electrónico] / Luis Vicente Syro Moreno, . - 2021.
Obra : Pituitary
Idioma : Inglés (eng)
Palabras clave : Consensus Delphi Endoscopic endonasal Endoscopic transsphenoidal surgery Pituitary Pituitary adenoma Skull base surgery Resumen : Purpose: Surgical workflow analysis seeks to systematically break down operations into hierarchal components. It facilitates education, training, and understanding of surgical variations. There are known educational demands and variations in surgical practice in endoscopic transsphenoidal approaches to pituitary adenomas. Through an iterative consensus process, we generated a surgical workflow reflective of contemporary surgical practice. Methods: A mixed-methods consensus process composed of a literature review and iterative Delphi surveys was carried out within the Pituitary Society. Each round of the survey was repeated until data saturation and > 90% consensus was reached. Results: There was a 100% response rate and no attrition across both Delphi rounds. Eighteen international expert panel members participated. An extensive workflow of 4 phases (nasal, sphenoid, sellar and closure) and 40 steps, with associated technical errors and adverse events, were agreed upon by 100% of panel members across rounds. Both core and case-specific or surgeon-specific variations in operative steps were captured. Conclusions: Through an international expert panel consensus, a workflow for the performance of endoscopic transsphenoidal pituitary adenoma resection has been generated. This workflow captures a wide range of contemporary operative practice. The agreed "core" steps will serve as a foundation for education, training, assessment and technological development (e.g. models and simulators). The "optional" steps highlight areas of heterogeneity of practice that will benefit from further research (e.g. methods of skull base repair). Further adjustments could be made to increase applicability around the world. Mención de responsabilidad : Hani J. Marcus, Danyal Z. Khan, Anouk Borg, Michael Buchfelder, Justin S. Cetas, Justin W. Collins, Neil L. Dorward, Maria Fleseriu, Mark Gurnell, Mohsen Javadpour, Pamela S. Jones, Chan Hee Koh, Hugo Layard Horsfall, Adam N. Mamelak, Pietro Mortini, William Muirhead, Nelson M. Oyesiku, Theodore H. Schwartz, Saurabh Sinha, Danail Stoyanov, Luis V. Syro, Georgios Tsermoulas, Adam Williams, Mark J. Winder, Gabriel Zada & Edward R. Laws Referencia : Pituitary. 2021 Dec;24(6):839-853. DOI (Digital Object Identifier) : 10.1007/s11102-021-01162-3 PMID : 34231079 Derechos de uso : CC BY En línea : https://link.springer.com/article/10.1007%2Fs11102-021-01162-3 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5816 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001750 AC-2021-066 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
2021-066Adobe Acrobat PDF
Título : Selective molecular biomarkers to predict biologic behavior in pituitary tumors Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2017 Títulos uniformes : Expert Review of Endocrinology and Metabolism Idioma : Inglés (eng) Palabras clave : ENC1 gene endocan EZH2 FSCN1 invasion-associated genes molecular biomarkers neuropilin (NRP-1) oncogene-induced senescence pituitary adenoma TACSTD family (EpCAM TROP2) Resumen : Introduction: To date, several cell proliferation markers, apoptosis, vascular markers, oncogenes, tumor suppressor genes, cell cycle mediators, microRNA (miRNAs), and long noncoding RNAs (lncRNAs) have been identified to be involved in the tumorigenesis, migration, proliferation and invasiveness of pituitary adenomas. There are still no reliable morphologic markers predictive of pituitary adenoma recurrence. Recent scientific research introduced new techniques to enable us to attain new information on the genesis and biologic behavior of pituitary adenomas. Areas covered: This review covers selected, compelling and cumulative information in regards to TACSTD family (EpCAM, TROP2), neuropilin (NRP-1), oncogene-induced senescence (OIS), fascins (FSCN1), invasion-associated genes (CLDN7, CNTNAP2, ITGA6, JAM3, PTPRC and CTNNA1) EZH2, and ENC1 genes and endocan. Expert commentary: Ongoing research provides clinicians, surgeons and researchers with new information not only on diverse pathways in tumorigenesis but also on the clinical aggressive behavior of pituitary adenomas. Newly developed molecular techniques, bioinformatics and new pharmaceutical drug options are helpful tools to widen the perspectives in our understanding of the complex nature of pituitary tumorigenesis. The discovery of new molecular biomarkers can only be accomplished by continuing to investigate pituitary embryogenesis, histogenesis and tumorigenesis. Mención de responsabilidad : Aydin Sav, Fabio Rotondo, Luis V Syro, Meric A Altinoz, Kalman Kovacs Referencia : Expert Rev Endocrinol Metab. 2017 May;12(3):177-185. DOI (Digital Object Identifier) : 10.1080/17446651.2017.1312341 PMID : 30063456 En línea : https://www.tandfonline.com/doi/full/10.1080/17446651.2017.1312341 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4066 Selective molecular biomarkers to predict biologic behavior in pituitary tumors [documento electrónico] / Luis Vicente Syro Moreno, . - 2017.
Obra : Expert Review of Endocrinology and Metabolism
Idioma : Inglés (eng)
Palabras clave : ENC1 gene endocan EZH2 FSCN1 invasion-associated genes molecular biomarkers neuropilin (NRP-1) oncogene-induced senescence pituitary adenoma TACSTD family (EpCAM TROP2) Resumen : Introduction: To date, several cell proliferation markers, apoptosis, vascular markers, oncogenes, tumor suppressor genes, cell cycle mediators, microRNA (miRNAs), and long noncoding RNAs (lncRNAs) have been identified to be involved in the tumorigenesis, migration, proliferation and invasiveness of pituitary adenomas. There are still no reliable morphologic markers predictive of pituitary adenoma recurrence. Recent scientific research introduced new techniques to enable us to attain new information on the genesis and biologic behavior of pituitary adenomas. Areas covered: This review covers selected, compelling and cumulative information in regards to TACSTD family (EpCAM, TROP2), neuropilin (NRP-1), oncogene-induced senescence (OIS), fascins (FSCN1), invasion-associated genes (CLDN7, CNTNAP2, ITGA6, JAM3, PTPRC and CTNNA1) EZH2, and ENC1 genes and endocan. Expert commentary: Ongoing research provides clinicians, surgeons and researchers with new information not only on diverse pathways in tumorigenesis but also on the clinical aggressive behavior of pituitary adenomas. Newly developed molecular techniques, bioinformatics and new pharmaceutical drug options are helpful tools to widen the perspectives in our understanding of the complex nature of pituitary tumorigenesis. The discovery of new molecular biomarkers can only be accomplished by continuing to investigate pituitary embryogenesis, histogenesis and tumorigenesis. Mención de responsabilidad : Aydin Sav, Fabio Rotondo, Luis V Syro, Meric A Altinoz, Kalman Kovacs Referencia : Expert Rev Endocrinol Metab. 2017 May;12(3):177-185. DOI (Digital Object Identifier) : 10.1080/17446651.2017.1312341 PMID : 30063456 En línea : https://www.tandfonline.com/doi/full/10.1080/17446651.2017.1312341 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4066 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000668 AC-2017-057 Archivo digital Producción Científica Artículos científicos Disponible
Título : Vasculogenic Mimicry in Clinically Non-functioning Pituitary Adenomas : a Histologic Study Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2017 Títulos uniformes : Pathology and Oncology Research Idioma : Inglés (eng) Palabras clave : Biomarkers pathology pituitary adenoma microvascularity vasculogenic mimicry Resumen : The term “vasculogenic mimicry” (VM) refers to the phenomenon in which vascular-like channels, which are not lined by endothelial cells, are formed in tumors. Since its discovery in 1999, it has been observed in several tumor types and is proposed to provide blood perfusion to tumors in absence of co-apted or neo-angiogenic blood vessels. Pituitary tumors are generally slow growing, benign adenomas which are less vascularized than the normal pituitary gland. To date, VM in pituitary adenomas has not been described. In this histological study, we assessed the presence of VM in a series of surgically resected clinically non-functioning pituitary adenomas (NFPAs) using CD34 and Periodic Acid-Schiff (PAS) double staining. To identify VM, slides were assessed for the presence of CD34-negative and PAS-positive channels indicating that they were not lined by endothelial cells. The histological staining pattern suggestive of VM was noted in 22/49 (44.9%) of the specimens studied. VM was observed in both recurring and non-recurring NFPAs. The incidence of VM present varied from case to case and within groups. There was no association between the presence of VM and gender, tumor size, Ki-67 index, recurrence or cavernous sinus invasion. VM was not noted in cases of non-tumorous pituitaries. Our findings suggest the existence of a complementary perfusion system in pituitary adenomas, implying potential clinical implications with respect to response to therapy and clinical course. Further research is warranted to confirm the presence of VM in pituitary adenomas to elucidate its clinical relevance in patients diagnosed with a pituitary adenoma. Mención de responsabilidad : Joseph Di Michele, Fabio Rotondo, Kalman Kovacs, Luis V Syro, George M Yousef, Michael D Cusimano, Antonio Di Ieva Referencia : Pathol Oncol Res. 2017 Oct;23(4):803-809. DOI (Digital Object Identifier) : 10.1007/s12253-017-0196-4 PMID : 28084580 En línea : https://link.springer.com/article/10.1007%2Fs12253-017-0196-4 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4030 Vasculogenic Mimicry in Clinically Non-functioning Pituitary Adenomas : a Histologic Study [documento electrónico] / Luis Vicente Syro Moreno, . - 2017.
Obra : Pathology and Oncology Research
Idioma : Inglés (eng)
Palabras clave : Biomarkers pathology pituitary adenoma microvascularity vasculogenic mimicry Resumen : The term “vasculogenic mimicry” (VM) refers to the phenomenon in which vascular-like channels, which are not lined by endothelial cells, are formed in tumors. Since its discovery in 1999, it has been observed in several tumor types and is proposed to provide blood perfusion to tumors in absence of co-apted or neo-angiogenic blood vessels. Pituitary tumors are generally slow growing, benign adenomas which are less vascularized than the normal pituitary gland. To date, VM in pituitary adenomas has not been described. In this histological study, we assessed the presence of VM in a series of surgically resected clinically non-functioning pituitary adenomas (NFPAs) using CD34 and Periodic Acid-Schiff (PAS) double staining. To identify VM, slides were assessed for the presence of CD34-negative and PAS-positive channels indicating that they were not lined by endothelial cells. The histological staining pattern suggestive of VM was noted in 22/49 (44.9%) of the specimens studied. VM was observed in both recurring and non-recurring NFPAs. The incidence of VM present varied from case to case and within groups. There was no association between the presence of VM and gender, tumor size, Ki-67 index, recurrence or cavernous sinus invasion. VM was not noted in cases of non-tumorous pituitaries. Our findings suggest the existence of a complementary perfusion system in pituitary adenomas, implying potential clinical implications with respect to response to therapy and clinical course. Further research is warranted to confirm the presence of VM in pituitary adenomas to elucidate its clinical relevance in patients diagnosed with a pituitary adenoma. Mención de responsabilidad : Joseph Di Michele, Fabio Rotondo, Kalman Kovacs, Luis V Syro, George M Yousef, Michael D Cusimano, Antonio Di Ieva Referencia : Pathol Oncol Res. 2017 Oct;23(4):803-809. DOI (Digital Object Identifier) : 10.1007/s12253-017-0196-4 PMID : 28084580 En línea : https://link.springer.com/article/10.1007%2Fs12253-017-0196-4 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4030 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000625 AC-2017-014 Archivo digital Producción Científica Artículos científicos Disponible PermalinkPermalinkPermalinkPermalinkPermalink
